A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02138734 |
|
Recruitment Status :
Recruiting
First Posted : May 15, 2014
Last Update Posted : August 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-muscle Invasive Bladder Cancer | Biological: BCG+N-803 Biological: BCG | Phase 1 Phase 2 |
The study includes a dose escalation phase (phase Ib) and an expansion phase (phase IIb).
In the phase Ib, patients will be treated with intravesical N-803 in combination with BCG. The purpose of the phase Ib portion of the study is to evaluate the safety, identify the Maximum Tolerated Dose (MTD) of N-803 and determine the Recommended Dose (RD) level of N-803 in combination with BCG for the phase IIb expansion.
In the phase IIb expansion, patients will be randomized to receive either intravesical N-803 in combination with BCG or BCG alone. Patients will be enrolled into one of two study cohorts (Cohort A and Cohort B). These will be two independent study cohorts, evaluated separately for treatment efficacy.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 596 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Single arm phase Ib. Two-arm phase IIb, two-cohort: each randomized 1:1 via randomization scheme stratified by disease and ECOG status. Cohort A: patients with CIS disease (with or without Ta/T1); planned enrollment = 366 Cohort B: patients with high-grade papillary disease (Ta/T1 only); planned enrollment = 230 |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer |
| Actual Study Start Date : | July 21, 2014 |
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | December 2027 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: N-803+BCG
(Phase Ib and IIb) for BCG-naive patients
|
Biological: BCG+N-803
BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, & 18 months. An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included. |
|
Active Comparator: BCG alone
(Phase IIb) for BCG-naive patients
|
Biological: BCG
BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, & 18 months. An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included. |
- Complete Response (CR) Rate [ Time Frame: 12 months ]For phase IIb patients in Cohort A: compare complete response rate between treatment arms using cystoscopy, confirmatory bladder biopsy and urine cytology.
- Disease Free Survival (DFS) [ Time Frame: 24 months ]For phase IIb patients in Cohort B: compare disease-free survival between treatment arms using cystoscopy, confirmatory bladder biopsy and urine cytology.
- Progression-free survival (PFS) [ Time Frame: 24 months ]For phase IIb, Cohorts A & B: time from randomization to disease progression or death
- Overall survival [ Time Frame: 24 months ]For phase Ib and IIb: all enrolled patients will be followed for 2 years to determine survival.
- Disease specific survival [ Time Frame: 24 months ]For phase IIb, Cohorts A & B: time from randomization to death resulting from bladder cancer
- Time to disease worsening [ Time Frame: 24 months ]For phase IIb, Cohorts A & B: cystectomy or change in therapy indicative of more advanced disease, including systemic chemotherapy or radiation therapy
- Time to cystectomy [ Time Frame: 24 months ]For phase IIb, Cohorts A & B: time from randomization to cystectomy
- Safety Profile: Number and severity of treatment related AEs [ Time Frame: 48 months ]For phase Ib and phase IIb Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment.
- Immunogenicity: serum level of anti-N-803 in patient samples [ Time Frame: 24 months ]For phase Ib and IIb Measures the serum level of anti-N-803 in patient samples.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
-
Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology).
- Cohort A: Histologically confirmed CIS (with or without Ta/T1 disease); Cohort B: Histologically confirmed high-grade papillary disease (Ta/T1 only).
- Patients are eligible if the diagnostic biopsy was done within 3 months of treatment start and a cystoscopy demonstrating no resectable disease was done within 6 calendar weeks (inclusive of 48 days) of treatment start (residual CIS is acceptable; patients with T1 disease must undergo repeat resection if muscularis propria is not present in each biopsy sample). Patients with high-grade Ta and/or T1 disease should have complete resection before study treatment.
- Upper tract imaging within 6 months prior to study entry must not be suspicious for upper tract malignancy.
- Currently eligible for intravesical BCG therapy.
- Age ≥ 18 years.
- Performance status: ECOG performance status of 0, 1, or 2.
-
Laboratory tests performed within 21 days of treatment start:
- Absolute neutrophil count (AGC/ANC) ≥ 1,000/µL
- Platelets ≥ 100,000/µL [Patients may be transfused to meet this requirement]
- Hemoglobin ≥ 8 g/dL [Patients may be transfused to meet this requirement]
- Calculated glomerular filtration rate (GFR*) >40 mL/min or Serum creatinine ≤ 1.5 x ULN
- Total bilirubin ≤ 2.0 X ULN
- AST, ALT, ALP ≤ 3.0 X ULN
- Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction. PFT > 50% FEV1 if clinically indicated by the investigator.
- Negative serum pregnancy test if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized).
- Female participants of childbearing potential must adhere to using a medically accepted method of birth control prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study.
-
Provide signed informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations.
- using the following Cockcroft-Gault equation to calculate the eGFR for this study: eGFR in mL/min = {(140-age in years) x (weight in kg) x F}/(serum creatinine in mg/dL x 72) Where F =1 if male; and 0.85 if female
Exclusion Criteria
- Prior BCG treatment or known hypersensitivity to BCG. Patients who have received more than a single-dose post-operative treatment of mitomycin-C or gemcitabine following the most recent screening TURBT/biopsy are excluded.
- Concurrent use of other investigational agents (not including FDA-authorized drugs for the prevention and treatment of COVID-19).
- History of or evidence of muscle-invasive, locally advanced, metastatic and/or extravesical bladder cancer or any other cancer within the past 5 years, except: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage 1 or 2 cancer from which the patient is currently in complete remission, or stable prostate cancer (under active surveillance or hormone control).
- Symptomatic congestive heart failure (CHF), NYHA (New York Heart Association) Class III or IV or other clinical signs of severe cardiac dysfunction.
- Severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry.
- History or evidence of uncontrollable CNS disease.
- Known HIV-positive.
- Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
- Concurrent febrile illness, active urinary tract infection, active tuberculosis, a history of hypotension or anaphylactic reactions.
- Ongoing chronic systemic steroid therapy required (>10 mg oral prednisone daily or equivalent).
- Women who are pregnant or nursing. Female patients of childbearing potential must have a negative pregnancy test and must adhere to using a medically acceptable method of birth control prior to screening and agree to continue its use during the study and for 30 days after the last dose of study drug, or be surgically sterilized (e.g., hysterectomy or tubal ligation). Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Males must agree to use barrier methods of birth control while on study and for 90 days post last dose of study drug.
- Psychiatric illness/social situations that would limit compliance with study requirements.
- Other illness that in the opinion of the investigator would exclude the patient from participating in this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02138734
| Contact: Paula Bradshaw, MPH, MBA | 844-413-8500 | paula.bradshaw@immunitybio.com | |
| Contact: Atessa H Kiani, BS | 9499038749 | atessa.kiani@immunitybio.com |
Show 24 study locations
| Study Director: | Bobby Reddy, MD | ImmunityBio, Inc. |
| Responsible Party: | ImmunityBio, Inc. |
| ClinicalTrials.gov Identifier: | NCT02138734 |
| Other Study ID Numbers: |
CA-ALT-803-01-14; QUILT-2.005 |
| First Posted: | May 15, 2014 Key Record Dates |
| Last Update Posted: | August 3, 2022 |
| Last Verified: | August 2022 |
|
antitumor BCG bladder cancer cancer immunotherapy instillation interleukin-15 |
intravesical naive non-muscle invasive transitional cell carcinoma ALT-803 N-803 |
|
Urinary Bladder Neoplasms Non-Muscle Invasive Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Urogenital Diseases Urinary Bladder Diseases Urologic Diseases Male Urogenital Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |